Madrigal Pharmaceuticals, Inc. Stock News

An approval pathway for OCA in treating NASH still exists. But it appears to be a steeper path.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Catasys (CATS

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Entasis Therapeutics Holdings (ETTX – Research Report) today and set

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ObsEva SA

Here's a look at the top stocks that may remain in focus today

Oppenheimer analyst Jay Olson maintained a Buy rating on Marinus (MRNS – Research Report) yesterday and set a price target

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc.

Uncertainty over its NASH drug weighs on the stock.

Regulatory submission marks another major step toward commercialization of TAEUS liver device in 2020 ANN ARBOR, MI / ACCESSWIRE / June 30, 2020 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:

The Iowa senator’s comments could signal that there is little chance for a bill this year that would rein in drug prices, a policy that voters have expressed keen interest in.

Intercept Pharmaceuticals has accused the FDA of moving the goalposts during its review of a potential blockbuster drug for the fatty liver disease known as NASH following a rejection.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cryolife (CRY

Piper Sandler assumed coverage on shares of Legend Biotech (NASDAQ:PLRX) in a research note issued to investors on Monday morning, BenzingaRatingsTable reports. The brokerage issued an overweight rati

LOS ANGELES--(BUSINESS WIRE)--$ICPT #fraud--Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, today announced that it has commenced an investigation on